This report, based on a series of initial interviews, and augmented by an extensive survey to which 25 countries in total responded, describes policies and practices adopted by countries to address a number of challenges that are specific to oncology medicines.

This report argues for adjustments to regulatory governance traditions so that necessary changes can take place more quickly, at least cost to the economy and with the participation of all relevant stakeholders.